GSK Signs 500,000-Tonne Carbon Removal Deal with Varaha

GSK has committed to purchasing 500,000 tonnes of carbon removal credits over eight years through an agreement with Varaha, a carbon removal company. The deal sits within GSK's broader net-zero commitments, though the company has not disclosed the financial terms or the specific removal methodology Varaha employs.

This move reflects a pattern among large corporates: purchasing carbon removal credits to offset residual emissions that cannot be eliminated through direct operational cuts. The scale – 500,000 tonnes over eight years – averages 62,500 tonnes annually, a meaningful but modest portion of a multinational pharma operation's total footprint.

The critical question is whether GSK is using this as a substitute for emissions reduction or as a genuine complement. Carbon removal credits remain unproven at scale and face scrutiny over additionality, permanence, and measurement reliability. Varaha's specific methodology – whether direct air capture, biochar, enhanced weathering, or another approach – shapes the credibility of the offset claim. Without that detail, or third-party verification of the removal standard, this reads as a hedging bet rather than climate action.

For GSK, the agreement signals engagement with the carbon removal market at a time when major corporates are still figuring out how to integrate removal into net-zero pathways. For Varaha, it's validation of demand. But the sector-wide challenge remains: removal cannot replace aggressive emissions reduction in scopes 1, 2, and 3. Until GSK discloses its full decarbonisation roadmap – including capital investment in renewable energy, supply chain decoupling, and product redesign – this deal sits in the grey zone between credible climate strategy and carbon accounting theatre.